DOI: 10.36347/sjams.2020.v08i11.049

Pages: 2677-2684

The prevalence of overt and subclinical hypothyroidism (SCH) during pregnancy is reported to be 0.3-0.5% and 2-3% respectively. In about 5-18% of reproductive women, thyroid autoantibodies are present. Thyroid dysfunction (hypothyroidism, hyperthyroidism and autoimmune diseases) during pregnancy can lead to serious problems for both mother and baby. The multitude of adverse events associated with untreated thyroid disease during pregnancy leads to consider the potential benefits and costs of thyroid dysfunction testing before and during pregnancy. There is controversy over whether to treat subclinical thyroid dysfunction in pregnant women. This article reviews the most important studies associated with SCH and attempts to draw literature-based conclusions on the management of subclinical hypothyroidism in pregnancy.